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Heat shock protein 27 (HSP27) is traditionally viewed as an intracellular chaperone 
protein with anti-apoptotic properties. However, recent data indicate that a number of 
heat shock proteins, including HSP27, are also found in the extracellular space where 
they may signal via membrane receptors to alter gene transcription and cellular function. 
Therefore, there is increasing interest in better understanding how HSP27 is released 
from cells, its levels and composition in the extracellular space, and the cognate cell 
membrane receptors involved in effecting cell signaling. In this paper, the knowledge to 
date, as well as some emerging paradigms about the extracellular function of HSP27 
is presented. Of particular interest is the role of HSP27 in attenuating atherogenesis 
by modifying lipid uptake and inflammation in the plaque. Moreover, the abundance 
of HSP27 in serum is an emerging new biomarker for ischemic events. Finally, HSP27 
replacement therapy may represent a novel therapeutic opportunity for chronic inflam-
matory disorders, such as atherosclerosis.
Keywords: heat shock protein 27, inflammation, atherosclerosis, coronary artery disease, HSPB1, non-classical 
secretion, extracellular HSP27
iNTRODUCTiON
Since its first discovery in 1962 by Ritossa, the heat shock response has been established as the 
classical molecular mechanism underlying the cellular response to heat stress, involving the upregu-
lation of a spectrum of protein families designated as “heat shock proteins” (HSPs) (1, 2). These 
proteins range in molecular weight from 10 to 110  kDa and primarily function as “chaperones” 
that facilitate proper protein folding (3, 4). Exposed hydrophobic residues in nascent or misfolded 
proteins act as the signal to recruit and activate HSPs, making this class of proteins powerful sen-
sors of environmental (e.g., heat, oxidative) and physiological (e.g., infection, inflammation) stress 
(5, 6). Although initially characterized as intracellular chaperones, subsequent studies pointed to 
the presence of HSPs in the extracellular space (7, 8). Extracellular HSPs (eHSPs) have consequently 
been ascribed novel functions (such as “outside–in” signaling leading to cellular proliferation and 
immune response modulation), expanding their canonical role of maintaining homeostasis in the 
cell to that of the whole organism.
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iNTRACeLLULAR ROLe OF HSP27
Unlike the larger molecular weight HSPs, HSP27 was first identi-
fied as an estrogen-responsive protein (9–11), which was later 
confirmed to be heat-inducible and sharing sequence homology 
with other HSPs (12–16). It is a member of the small heat shock 
protein beta (HSPB) family, an HSP subgroup characterized 
by a lower molecular weight range (12–43  kDa) and a shared 
α-crystallin domain flanked by variable N- and C-terminal 
sequences (17, 18). The encoding gene, HSPB1, is located on 
chromosome 7 (7q11.23) (19), and its associated mutations have 
been linked to Charcot–Marie–Tooth disease type 2 (20,  21) 
and possibly Williams syndrome (22, 23). The intracellular 
chaperoning function of HSP27 is largely regulated by the phos-
phorylation/dephosphorylation of three key N-terminal serine 
residues at positions 15, 78, and 82 (24–26), which influences the 
assembly of HSP27 monomers into large oligomeric complexes 
(200–800  kDa). Such complexes create an ATP-independent 
chaperone network that effectively traps misfolded protein 
substrates, preventing their aggregation through a series of 
controlled binding and release reactions that, in conjunction 
with other larger HSPs (HSP70, HSP90), facilitate their correct 
folding (27–29). Thus, in concert with other chaperones, HSP27 
maintains cellular homeostasis by holding misfolded proteins 
in a soluble, refolding-competent form. Intracellular HSP27 has 
also been implicated in (i) cytoskeletal architecture and dynamics 
(30–32), (ii) mRNA stabilization (33), (iii) antioxidant responses 
(34–36), and (iv) anti-apoptosis (37–40). Not surprisingly, its 
multiple, cytoprotective effects are associated with the ameliora-
tion of a range of pathological conditions, including degenerative, 
ischemic, neurological, and cardiovascular disease (41). For more 
comprehensive reviews on the biology of intracellular HSP27, 
several references are available (17, 42–44).
eXTRACeLLULAR ROLe OF HSP27
Heat shock proteins were first observed in the extracellular space 
nearly 30  years ago as proteins that were transferred from glia 
to neurons in the squid giant axon (45) and later confirmed to 
be released after heat shock in mammalian cells (46). Like other 
HSPs, HSP27 has been found extracellularly  –  initial evidence 
indicated its secretion from tumor cells (47–51). The presence 
of HSP27 has been detected in human serum, with elevations 
observed after extreme exercise (52, 53). Increases in serum 
HSP27 have also been measured in patients with chronic pan-
creatitis (54), gastric adenocarcinoma (55), insulin resistance 
(56), and during acute attacks in multiple sclerosis (57), while 
decreases have been associated with type 1 diabetes (58). HSP27 
has also been found in the cerebrospinal fluid during brain and 
spinal cord ischemia (59).
In the context of cardiovascular disease, two independent 
groups utilizing a proteomic analysis of human atherogenic arte-
rial tissue have shown that HSP27 is differentially secreted into 
the extracellular milieu (60, 61). Moreover, serum levels of HSP27 
have been detected in patients with atherosclerosis (60, 62, 63), 
acute coronary syndromes (61), and reperfusion after ischemic 
clamping during heart bypass surgery (64). The presence of 
serum HSP27 was confirmed in an atherosclerosis mouse model 
(ApoE−/−), overexpressing HSP27 (HSP27o/e) using commercially 
available ELISA kits (65, 66). However, these experiments 
revealed the presence of HSP27-reactive autoantibodies (AAB) in 
the serum that effectively shield the detection of HSP27, thereby 
resulting in erroneously low levels of HSP27. Consequently, our 
laboratory has developed a mass spectrometric-based method 
that can more sensitively detect serum HSP27 at levels higher 
than those quantified using commercial ELISA kits (67). Even 
though the detection of serum HSP27 levels can only improve, 
results to date firmly establish the extracellular presence of HSP27. 
However, key questions remain (1) how is HSP27 released from 
cells; (2) what is its function outside the cell; and (3) how does it 
signal from outside to inside the cell?
POSSiBLe MeCHANiSMS OF HSP27 
eXPORT
Secreted proteins typically exit eukaryotic cells via the endoplas-
mic reticulum–Golgi network (known as the “classical secretory 
pathway”). Such proteins contain an N-terminal signal peptide 
that marks them for secretion – which interestingly is absent in 
other types of secreted proteins, including HSPs. Several groups 
have shown that despite this, HSPs can still be released – for exam-
ple, early experiments that pharmacologically blocked the classi-
cal pathway still resulted in HSP secretion (in this case, HSP70) 
(46). Although HSP release was proposed to be a consequence 
of passive transport, i.e., necrosis (68), secretion can also occur 
independent of cell death, implying an active transport process 
that involves alternative, “non-classical” secretory mechanisms 
(46, 69–71). Indeed, some secretory proteins lacking the signal 
peptide for the classical pathway have since been identified, 
including interleukin (IL)-1a, IL-1b, and fibroblast growth factor 
(FGF)-2, and increasing evidence indicates that these proteins 
along with some HSPs are released by non-classical secretory 
pathways (7, 72, 73). Although there is still much mechanistic 
information to uncover regarding how HSP27 is secreted, this 
review will discuss a few key findings indicating that it may leave 
the cell via lysosomes and/or exosomes and bring up the possibil-
ity of direct protein translocation (Figure 1).
endolysosomal Pathway
Known as the recycling units of the cell, lysosomes are vesicular 
organelles containing enzymes that break down biomolecules 
(proteins, lipids, nucleic acids, carbohydrates) into their basic 
components. In addition to their role in the degradation of cel-
lular waste, lysosomes can also serve as storage compartments 
for proteins targeted for secretion. These “secretory lysosomes” 
have been found in blood cells, among other cell types, and 
share similarities with conventional lysosomes, including an 
acidic pH interior (82). Utilization of this alternative secretion 
pathway has been observed in the case of HSP70. In one study 
using prostate carcinoma cell lines, lysosomal fractions contained 
more HSP70 following heat shock, and conversely, treatment with 
the lysosomal inhibitors, methylamine, and ammonium chloride 
prevented heat shock-mediated release of HSP70 into the culture 
FigURe 1 | Release of HSP27 involves non-classical secretory mechanisms. Experimental evidence suggests that HSP27 exits cells via the endolysosomal 
pathway and through exosomes. Localization of HSP27 to lysosomes (65) may involve the dephosphorylation of two serine residues at amino acids 15 and 82 (74); 
meanwhile, HSP70 appears to enter lysosomes with the aid of ABC transporters spanning the lysosomal membrane (75). Although direct protein translocation 
accounts for the unconventional secretion of FGF-2 (76, 77), it remains to be determined whether this mechanism plays a part in HSP27 extracellular release. Like 
FGF-2, HSP70 can interact with lipids as well as integrate into lipid membranes (7, 46, 78–81), and it also appears that HSP70 can integrate into artificial lipid 
bilayers forming channels.
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media  –  which together suggest that the lysosome is involved 
in secretion (75). It is likely that HSP70 enters the lysosomal 
interior via ATP-binding cassette (ABC) transporters, since inhi-
bition with glibenclamide, a general ABC transporter inhibitor, 
and DIDS, a specific ABCA1 inhibitor, reduced HSP70 release 
(75). As well, its release was associated with the relocalization 
of lysosomal markers, typically found in the lysosomal interior 
to the exterior cell membrane leaflet (75, 83). Taken together, 
these findings indicate that HSP70 may exit cells via secretory 
lysosomes, resulting in their fusion to the cell membrane. Similar 
findings were seen in cultured primary human peripheral blood 
mononuclear cells (PBMCs), whereby HSP70 secretion was 
significantly inhibited by the lysosomal inhibitor, methylamine, 
but not by brefeldin A (a blocker of transport from the ER to 
Golgi) (70). Furthermore, the presence of HSP70 in the lumen of 
lysosomes has been reported by another group (84).
What is the evidence that HSP27 uses the endolysosomal 
pathway? Findings from our laboratory have shown that upon 
treatment of macrophages with estradiol or acetylated low-
density lipoprotein (ac-LDL) – conditions that stimulate HSP27 
secretion  –  there was increased co-localization of HSP27 with 
the lysosomal markers, LAMP-1, and lysotracker (65). A later 
study yielded new insight into how HSP27 could be released 
through lysosomes (74). Their experiments utilized two types of 
HSP27 mutations, a constitutively phosphorylated mimic (S15D/
S82D) and a non-phosphorylatable form (S15A/S82A), which 
were linked to GFP in order to visualize cellular localization in 
endothelial (HUVEC) cells. Interestingly, it was observed that 
the S15A/S82A mutation co-localized more frequently with the 
lysosomal marker, LAMP-1, using fluorescence microscopy. 
Furthermore, using His-tagged HSP27 mutants expressed in 
HUVEC cells, the non-phosphorylatable HSP27 was once more 
found at higher levels in cell culture media compared to S15D/
S82D, as assessed by Western blotting for the histidine tag. These 
findings suggest that in order for HSP27 to localize to the lyso-
some (for subsequent secretion), these two serine residues must 
first be dephosphorylated (Figure 1).
exosomal Pathway
Exosomes are the most commonly accepted vehicle for HSP 
release (69). This type of secretory vesicle is derived from a mul-
tistep process that first involves the internalization of the plasma 
membrane to form endosomes, which then develop into late 
endosomes. Late endosomal membranes are invaginated within, 
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forming smaller vesicles (exosomes) that measure 40–100 nm in 
diameter and contain cytoplasmic components. These complex 
structures, referred to as “multivesicular bodies” (MVBs), fuse 
to the cell membrane, releasing exosomes into the extracellular 
space (Figure 1) (69, 85). Numerous findings have indicated the 
presence of several HSPs (HSP70, HSP60, HSP90) in exosomes, 
with localization observed at both the exosomal membrane 
(conceivably, facilitating interactions with cell surface receptors 
on target cells) and lumen (implying that for HSPs to have an 
effect on target cells, exosomes will have to burst to release their 
contents) (7, 86–90).
There is mounting evidence indicating that HSP27 is found 
in exosomes (Figure 1). HSP27 has been detected in exosomes 
derived from a variety of cell and tissue types, including keratino-
cytes, platelets, cancer cells, saliva, thymus, and urine, making 
the exosomal pathway a compelling system for HSP27 export 
(http://exocarta.org/gene_summary?gene_id=3315). Experi ments 
in B-lymphoblastoid cells also demonstrate the presence of 
HSP27 in exosomes (90). Here, basal levels of HSP27, HSP70, 
and HSP90 localized to exosome fractions as assessed by Western 
blotting  –  an effect that increased with duration of heat shock 
treatment. When isolated exosomes were coupled to beads for 
flow cytometry analysis, positive staining for exosomal surface 
markers (CD81 and MHC class I), but not HSPs, were noted, 
implying that these HSPs were not expressed on the exosomal 
surface. However, when the exosome–bead complexes were 
solubilized by boiling in SDS (disrupting the exosomes) and 
total protein analyzed by Western blotting, elevated levels of 
HSP70 were detected in exosomes from heat-shocked cells 
compared to controls. These findings indicate that disruption of 
the exosomal membrane was required in order to detect HSP70, 
implying its localization within the exosome. Unfortunately, 
experiments detecting HSP27 after exosomal disruption were not 
presented in this study, thus it could not be confirmed whether 
the absence of HSP27 in the exosomal membrane points to a 
luminal presence. Results from our laboratory also support that 
exosomes may be one system involved in HSP27 release, since 
the treatment of human macrophages with an exosomal inhibitor, 
dimethyl amiloride (DMA), substantially decreased extracel-
lular HSP27 levels (66). More recently, HSP27 was detected in 
exosomal fractions originating from primary cultures of rat 
astrocytes (91). Consensus has yet to be achieved with regards 
to the precise location of HSPs in exosomes. The suggestion of 
a luminal localization for HSP70 (90) is in contrast to results in 
macrophages infected with two different viruses (88, 92) and in 
blood cells after ischemic preconditioning (87), which indicate 
the presence of HSP70 in the exosomal membrane. Differences 
in exosomal localization is likely determined by the type of HSP, 
the cell from which exosomes originate, and the kind of stimuli 
triggering exosomal release (e.g., heat shock vs. viral infection). 
Another aspect of the exosomal pathway that is worth further 
exploration is determining the sorting signal that directs HSPs to 
populate exosomes. In the case of HSP60, for example, it appears 
to be ubiquitinated in exosomal fractions (86), suggesting that 
ubiquitinylation may signal sorting to exosomes. Whether this 
applies to HSP27 is currently unknown.
Direct Protein Translocation
A final, intriguing possibility for HSP27 export may involve direct 
protein translocation across the plasma membrane, as has been 
proposed for FGF-2 (73, 93). Exit of HSPs from cells could be 
mediated by transmembrane proteins, like ABC transporters 
(also located on cell membranes), which, as already mentioned, 
are instrumental in transporting HSP70 in the lysosomes for 
secretion (75, 83). Another hypothetical way for HSPs to leave the 
cell is by directly associating with the cell membrane, which could 
then somehow facilitate their extracellular release. In fact, such 
lipid interactions have been observed with HSP70 (Figure  1) 
(46, 78–80), and it also appears that HSP70 can integrate into 
artificial lipid bilayers forming channels (7, 81). Despite the lack 
of evidence supporting the direct release of HSP70 (and other 
HSPs) after insertion or association into lipid membranes, it is 
still possible to consider direct membrane translocation of HSPs 
as a mechanism for exit from cells by looking to the cellular 
export paradigm utilized by FGF-2.
Over the years, the Nickel research group has systematically 
delineated the various steps involved in the export mechanism 
for FGF-2 (76, 77). According to their findings, FGF-2 localizes 
to the inner leaflet of the cell membrane via interactions with 
lipids, and after phosphorylation by Tec kinase, is then primed to 
oligomerize and integrate into the membrane, forming a transient 
pore structure, which itself is speculated to disassemble into 
FGF-2 monomers during extracellular release (76). Subsequent 
results highlight the importance of two surface cysteines unique 
to FGF-2 (notably absent in other FGF family members) that 
mediate disulfide bond formation with another FGF-2 monomer, 
forming dimers that then assemble into hexamers  –  the final 
FGF-2 structural complex that is inserted into the membrane (93). 
Since mutations of these two cysteines abrogate FGF-2 secretion, 
it appears that disulfide formation between cysteines facilitates 
the insertion of FGF-2 oligomers into the cell membrane and 
its subsequent release (93). Perhaps, similar mechanisms are 
involved with HSP export. FGF-2 and HSP70 have both been 
observed to interact with lipids and integrate into membranes. 
In addition, HSP27 also shares a key feature with FGF-2 – both 
contain unique cysteine (C) residues that happen to be missing 
in members of their respective protein families. In HSP27, this 
unique cysteine residue, C137, located in the α-crystallin domain, 
also mediates dimerization with other HSP27 monomers, how-
ever the consequence of dimerization differs in that disulfide 
formation between opposing cysteine residues modulates HSP27 
function during oxidative stress (94). In reducing conditions, 
cysteines are directly opposite each other at the dimer interface, 
while under oxidative conditions, a disulfide bond forms, altering 
the structure of HSP27’s α-crystallin domain, leading to increased 
exposure of hydrophobic residues and promoting chaperoning 
activity (95–97). Although C137 is thought to be critical in medi-
ating HSP27’s chaperoning activity during oxidative stress (i.e., 
disulfide bond can more easily bind to misfolded proteins that 
arise from oxidative stress), it will be interesting to see if mutation 
of this cysteine can alter secretion of HSP27, as has been observed 
with FGF-2. Another issue to address is whether HSP27 can inter-
act with membrane lipids, like HSP70 (98–100). There is much 
FigURe 2 | extracellular HSP27 (eHSP27) can trigger TLR signaling, 
leading to NF-κB activation and cytokine upregulation (64, 103–106).
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to be discovered before ruling out that HSP27 could, in part, be 
exported from cells via direct protein transport (Figure 1).
SigNALiNg OF eXTRACeLLULAR HSP27
Once outside the cell, what does extracellular HSP27 do? Most 
evidence suggests that, like other HSPs, HSP27 serves as a signal-
ing molecule released by cells, which bind to surface receptors 
on distant cellular targets, such as endothelial and immune cells 
(7, 101, 102). Thus far, it appears that HSP27 can function outside 
the cell as (i) an uncomplexed, extracellular protein, (ii) part of a 
larger protein complex, for example, via interactions with AAB 
in the serum, and (iii) molecular cargoes located on the surface 
or inside exosomes. This review will focus on how recombinant 
extracellular HSP27 modifies receptor-mediated signaling in 
target cells and will only briefly comment on its effects as part of 
antibody complexes and exosomes.
Several cell membrane receptors have been identified for 
eHSPs, including CD91, CD40, CD36, CD14, toll-like receptors 
(TLRs), and scavenger receptor-A (SR-A) (8, 102). HSP27 has also 
been shown to interact with TLRs, as well as other types of recep-
tors, altering signaling mechanisms in a variety of cell types and 
conditions (Figure 2). For example, HSP27 treatment of human 
macrophages promoted NF-κB transcriptional activation as well 
as protein expression and secretion of the NF-κB-dependent 
cytokines, GM-CSF and IL-10  –  the latter important in anti-
inflammatory responses (103). NF-κB activation by HSP27 was 
also observed in mouse coronary endothelial cells, occurring via 
interactions with TLR-2 and TLR-4 and resulting in the upregula-
tion of intercellular adhesion molecule-1 (ICAM-1) and mono-
cyte chemoattractant protein-1 (MCP-1) (64). In human coronary 
endothelial cells, HSP27 also upregulated ICAM-1, MCP-1, as well 
as IL-6 and IL-8, although the receptors mediating the response 
in human cells were not identified (64). In contrast, TLR-3 was 
implicated as the receptor utilized by HSP27 in human microvas-
cular endothelial cells, leading to NF-κB activation and secretion 
of IL-8 and vascular endothelial growth factor (VEGF) (104). 
The effect of HSP27 on VEGF was corroborated in endothelial 
progenitor cells (EPCs), although this study did not address which 
receptors play a part in VEGF secretion (105). HSP27 increased 
secretion of IL-6 in bone marrow-derived dendritic cells, as well 
as TNF-α, IL-1β, IL-12p35, and IL-12p40, which partly occurred 
through TLR-4 signaling (106). In primary human monocytes, 
release of IL-10 by HSP27 involved phosphorylation of p38 and 
MAPKAPK-2, while increased TNF-α levels were attributed to 
the activation of both p38 and ERK1/2 signaling pathways (107). 
HSP27 also interacts with estrogen receptor-β (ER-β) (108, 109). 
Altogether, these findings implicate extracellular HSP27 in (i) 
immune signaling (via activation of TLR signaling pathways), 
leading to cytokine production and modulation of the immune 
response, (ii) cellular migration (due to the upregulation of 
ICAM-1 and VEGF), and (iii) cellular proliferation (through its 
interactions with ER-β).
Extracellular HSP27 has also been found as part of larger mac-
romolecular complexes. For example, our laboratory’s attempts to 
develop a more sensitive method for measuring HSP27 in serum 
samples led to the serendipitous discovery that this protein is 
complexed to AAB, which effectively shields the detection of 
serum HSP27. In vitro experiments later showed that AAB could 
potentiate the signaling effects of HSP27 (67). Another example of 
HSP27 being part of a larger complex is its presence in exosomes. 
Exosomes carrying HSP27 (either on the surface or in its interior) 
could then interact with target cells through receptor interactions 
leading to endocytosis, or by simple membrane fusion that is 
independent of receptors (69). Precisely how exosomes cargoing 
HSP27 affect target cells is unknown; however, it may instigate 
a variety of effects depending on the exosomal source and 
downstream cellular target. This has been observed with HSP70, 
whose expression on exosomal surfaces has been found to (i) 
trigger TLR-4 signaling leading to myocardial protection (87) 
and (ii) stimulate natural killer (NK) cells, increasing its cytolytic 
activity against HSP70-membrane positive tumors (110). Thus, 
by interacting with receptors on both immune and endothelial 
cells, leading to the differential release of cytokines and growth 
factors, extracellular HSP27 is a potentially important modulator 
of the immune response – an important process that contributes 
to atherosclerosis.
HSP27 iN ATHeROSCLeROSiS
Atherosclerosis is a chronic cardiovascular condition that is 
marked by the progressive accumulation of inflammatory scar 
tissue containing lipid deposits, calcification, and necrotic debris 
within the walls of arteries that can lead to the formation of 
unstable plaques at risk of rupture. Plaque rupture is unpredict-
able and is the final phase that leads to a reduction in blood flow, 
ischemia in the distal vascular bed, and clinical symptoms or 
events (e.g., heart attack and/or death). Although the etiology of 
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atherosclerosis was primarily thought to originate from a lipid/
cholesterol imbalance (be it genetic or environmental), it appears 
that atheroprogression is a complex, multifactorial process that is, 
in part, due to coordinated immune responses. Recently, several 
lines of evidence support the emerging role of HSP27 in modulat-
ing atheroprogression, by altering the inflammatory components 
of atherosclerotic plaques.
Although evidence of cardiovascular disease has been traced 
back to thousands of years, with various prehistoric populations 
displaying signs of arterial plaque (111), it is only within the 
past 100  years that this condition has emerged as the leading 
cause of mortality in the world. Epidemiological studies from 
the twentieth century have indicated that women are at lower 
risk for developing cardiovascular diseases compared to men; 
however, this bias toward the female sex disappears after meno-
pause, implicating female hormones as protective factors against 
CVD (112). Consequently, various clinical trials conducted 
in the 1970s–2000s sought to test whether the replacement 
of ovarian hormones could protect menopausal women from 
CVD. Unfortunately, the conclusions of these trials indicate that 
hormone replacement therapy not only failed to protect women 
from CVD but also increased side effects as well as CVD risk (113, 
114). Although hormone replacement therapies were ineffective 
against CVD, the question of how the presence of female hor-
mones protect against CVD in premenopausal women remains. 
Given that HSP27 was initially identified as an estrogen-inducible 
gene (10, 11), it was hypothesized that HSP27 is one important 
downstream “foot soldier” of estrogen signaling that mediates 
cardiovascular protection (108).
There is a precedent in establishing a link between other HSPs 
and cardiovascular disease. For example, some studies correlate 
HSP60 with atherosclerosis severity and suggest that it could 
serve as a biomarker (115–117), while others associate HSP70 
serum levels with low CVD risk (118, 119). HSP27 was first impli-
cated in atherosclerosis more than 10 years ago, when a proteomic 
screen comparing levels of released proteins noted lower levels of 
HSP27 secretion from human atherosclerotic arteries compared 
to normal arteries (60). Indeed, HSP27 secretion and expression 
in atherosclerotic human coronary arteries (108, 120) decreases 
with increasing plaque progression, complexity, and instability. 
Conversely, areas of normal-appearing atherosclerotic arteries 
display increased HSP27 expression compared to plaque-filled 
areas from the same vessel (61). Three independent studies confirm 
the reduction in secreted HSP27 levels in atherosclerosis patients. 
The first study involving small patient cohorts (28 patients vs. 12 
controls) noted significantly lower HSP27 serum levels in CVD 
patients compared to healthy controls (60). Two later studies in 
larger patient cohorts (76 patients vs. 53 controls; 80 patients 
vs. 80 controls) validated this finding, with CVD patients again 
displaying lower levels of serum HSP27 (62, 63). Moreover, our 
laboratory also demonstrated that in patients diagnosed with 
coronary atherosclerosis (>50% stenosis by angiography), lower 
levels of HSP27 was predictive of subsequent major clinical events 
(i.e., heart attack, stroke, cardiovascular death) over a 5-year 
period (63). However, in a prospective, nested, case–controlled 
study involving initially healthy female participants who later 
developed cardiovascular disease, baseline HSP27 plasma levels 
are inversely associated with age but neither significantly associ-
ated with other established cardiovascular risk factors nor with 
future cardiovascular events (121). These seemingly disparate 
findings regarding HSP27’s potential as a marker in predicting 
cardiovascular events can be reconciled if one considers that all of 
the female subjects studied in the nested case–control series were, 
on average, 61 years of age at baseline and beyond menopause. 
Therefore, one would expect relatively low serum levels of HSP27 
in both the controls and later CVD event patients at baseline. 
Moreover, at this age, coronary atherogenesis may have already 
reached a moderately advanced stage.
Hence, the results to date reveal that plasma HSP27 levels may 
indeed be a potential marker for atherosclerosis and predictive of 
adverse cardiovascular events. With further refinements in the 
HSP27 serum assay that will remove the confounding presence 
of HSP27 AAB, we are confident that this conclusion will be fur-
ther validated. Additionally, diminished expression of HSP27 in 
atherosclerotic plaques compared to vessels free of disease further 
highlights the association between augmented HSP27 levels and 
protection against atherosclerosis.
Some investigators suggest that extracellular HSP27 may be 
subject to protease degradation that is more abundant in athero-
sclerotic compared to normal arteries. Indeed, it has been shown 
that plasmin is upregulated in atherosclerotic plaques and can 
cause the degradation and aggregation of recombinant HSP27 
(rHSP27) as well as HSP27 endogenously secreted from arterial 
explants  –  findings reversed by aprotinin, a specific plasmin 
inhibitor (122). Other enzymes that are more abundant in vul-
nerable atherosclerotic plaques due to a proteolytic imbalance, 
like matrix metalloproteases (MMPs) (123), can also interact 
with (124, 125) and possibly degrade HSPs (126). Another idea 
to consider is that HSP27 (as well as other HSPs) could function 
as “danger signals”  –  highly abundant self-proteins normally 
found intracellularly in healthy tissues, which are released into 
the extracellular space when tissues are damaged, infected, or 
stressed. Such danger signals are capable of activating antigen-
presenting cells (APCs) to initiate the adaptive immune response 
(127). Stress and damage associated with atheroprogression could 
thus release more HSP27 from cells into the circulation, resulting 
in the following possibilities: (i) less HSP27 expression in cells as 
plaque accumulates, (ii) proteolytic cleavage and degradation of 
extracellular HSP27, (iii) increased susceptibility to apoptosis of 
cells that have secreted HSP27, and (iv) activation/modulation of 
the immune response. Although the link between reduced HSP27 
levels in the serum and atherosclerotic vessel walls is strong, it 
remains unclear whether HSP27 levels are a secondary feature 
of atherosclerosis or the stress response during atherogenesis, or 
if HSP27 plays a causal role in directly modulating vessel wall 
homeostasis.
immunological Contribution in 
Atherosclerosis
In order to understand how HSP27 is involved in atheroprogres-
sion and whether it could protect against development of CVD, 
the various stages and key cellular players involved in atheroscle-
rosis must first be highlighted. Atherosclerosis is characterized 
FigURe 3 | Atherosclerotic plaque progression: severity of atherosclerosis correlates with increased infiltration of monocytes and their local 
activation into macrophages and foam cells, further promoting the inflammatory process (128, 129). HSP27 is expressed in normal areas of arteries, with 
reduction in expression in areas of advanced plaque (60, 61, 108, 120). Increases in HSP27 expression have also been noted in the fibrous cap and media (122).
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by the development in arteries of lesions or plaques containing 
lipids, inflammatory markers, and dead cells surrounded by a 
fibrotic cap structure. Some areas of the vasculature are more 
susceptible to plaque accumulation. For example, branch points 
in the circulatory tree experience altered laminar blood flow that 
could lead to atherosclerosis-promoting changes (128), including 
endothelial dysfunction, accumulation of oxidized low-density 
lipoproteins (ox-LDL), alterations in matrix protein composi-
tion, and accumulation of proteoglycans, which increase ox-LDL 
accumulation at the cellular level (129). Plaque accumulation 
can impair blood flow, causing health complications, and if left 
alone, can escalate to the grave consequence of plaque “rupture,” 
exposing pro-thrombotic (pro-clotting) material from the plaque 
to the blood and causing occlusion of the artery. These local 
arterial blood clots deprive nearby cells of oxygen, leading to cell 
death and various adverse outcomes (depending on the rupture 
site), including heart failure, stroke, renal impairment, and/or 
hypertension (129).
The first stage of plaque formation involves the development of 
“fatty streaks.” This gradual process originates in endothelial cells 
lining the inner arterial wall (“intima”) and involves (1) the uptake 
and accumulation of circulating oxidized lipids and low-density 
lipoprotein (LDL), (2) expression of adhesion molecules, and (3) 
chemokine release, resulting in the recruitment and deposition of 
immune cells (mainly lipid-containing macrophages also known 
as foam cells and T-cells) along the intima (130). Fatty streaks 
do not give rise to overt symptoms and are reversible (129). It is 
interesting to note that the partial attenuation of HSP27 expres-
sion starts in this stage of atherogenesis (Figure 3) (108, 131).
Over time, fatty streaks become mature atherosclerotic 
plaques (“atheromas”) distinguished by the following regions: (1) 
a core region, consisting of foam cells, lipids, immune cells, such 
as dendritic cells, mast cells, and B-cells (129), apoptotic cells, 
debris, cholesterol crystals (132–134), and proteases like plasmin 
(122); (2) a fibrous cap region surrounding the core, made up 
of smooth muscle cells (122) and a collagen-rich matrix; and 
(3) an interface between core and fibrous cap regions (“shoul-
der” region), housing mainly T-cells and macrophages (129) 
(Figure  3). Immunohistochemical analysis of atherosclerotic 
arteries obtained from patients undergoing cardiac surgery show 
HSP27 localization mainly in the fibrous cap and media (122); 
however, its abundance diminishes as the complexity and volume 
of the plaque increases (108).
The presence of immune cells early in plaque formation indi-
cates the involvement of the immune response; however, it is still 
unclear whether this promotes or attenuates atherosclerosis. The 
canonical idea that atherosclerosis is primarily caused by dietary 
and lifestyle factors still carries weight in that the rise of cardio-
vascular diseases came about within the last century, coinciding 
with increasingly sedentary lifestyles and increased caloric and 
fat intake. Given that fatty streaks are found in young people, 
it appears to be a normal adaptive process to have an immune 
response generated against lipids in the arteries. However, for 
this response to promote atheroprogression likely involves an 
interplay between the presence of cholesterol (in plaques) derived 
from the diet and circulating immune cells that become resident 
in the arterial wall. Hence, the human body can be tipped into 
developing atherosclerosis if the source of cholesterol becomes 
dysregulated (dietary or genetic predisposition to the develop-
ment of hypercholesterolemia) or if the immune system becomes 
abnormally sensitized to normal levels of lipid in the blood ves-
sels, or both.
The immune cells primarily responsible for propagating the 
inflammatory response against lipids in atherosclerotic plaque 
are macrophages. Upon encountering lipids, particularly ox-
LDL, macrophages engulf ox-LDL by binding to LDL membrane 
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receptors. Internalization of ox-LDL then triggers a cascade of 
events that transform macrophages into foam cells. Foam cells 
also secrete pro-inflammatory cytokines that result in the recruit-
ment and activation of additional immune cells to the lesion 
site – further amplifying the immune response and promoting the 
development of complex, advanced plaques. Our previous results 
have shown that HSP27 competes with LDL binding to SR-A, 
known to take up atherogenic lipids, as well as downregulating 
SR-A expression (65, 135), thus attenuating foam cell formation. 
Furthermore, administration of recombinant HSP27 has been 
shown to block the differentiation of monocytes to dendritic cells, 
a cell type that can also promote the pro-inflammatory process 
(136). Another way that HSP27 can regulate the inflammatory 
response involved in atherosclerotic plaque progression is through 
the release of GM-CSF, which we have seen in cultured human 
macrophages, following rHSP27 treatment (103). Depending on 
the existing cytokine milieu, GM-CSF appears to promote the 
development of the M1 macrophage lineage (137), considered 
to play a role in the pro-inflammatory immune response (138). 
HSP27 may thus favor the preponderance of one macrophage 
phenotype over another, thereby affecting plaque progression.
Finally, another immune cell type involved in atheroprogres-
sion (albeit to a lesser degree) are T-regulatory cells, which medi-
ate atheroprotection by amplifying the release of IL-10, thereby 
resulting in immune suppression (139–142). However, the role 
of HSP27 in T-regulatory function during atheroprogression is 
uncertain (143). Mast cells, a key cell type that populates ath-
erosclerotic plaque, are classically known to react immediately 
to allergens via cross-linking of cell surface IgE resulting in 
degranulation, histamine release, and synthesis of arachidonic 
acid metabolites, which can activate stress-signaling and pro-
apoptotic pathways (144). Mast cells have been shown to release 
proteases that can degrade HSP27 (145, 146).
Potential Mechanisms involved in  
HSP27-Mediated Atheroprotection
The key findings from our research group and others showing 
that (i) the loss of HSP27 serum levels correlates with plaque and 
disease progression and (ii) HSP27 is absent at sites of mature, 
complex plaque (while present in normal intima from the same 
patient with atherosclerosis), suggest that HSP27 could be 
atheroprotective. To address this possibility, mice prone to ather-
osclerosis (ApoE−/−) (147) were crossed to transgenic mice over-
expressing (human) HSP27 (HSP27o/e) (65). Circulating HSP27 
serum levels were higher in HSP27o/e ApoE−/− mice compared to 
ApoE−/− control mice and were inversely correlated with lesion 
area in both male and female mice (65, 148). More importantly, 
HSP27 overexpression protected mice from atherosclerosis, 
particularly in female mice (65) – a process that was abrogated 
by ovariectomy but rescued by administration of exogenous 
estrogens (66). Taken together, these data indicate that secretion 
of HSP27 into the circulation requires estrogens (66). Compared 
to ApoE−/− mice, HSP27o/e ApoE−/− mice exhibited reductions 
in cholesterol cleft areas, macrophage infiltration, apoptotic cell 
number in the plaques, and free serum cholesterol. Features 
indicative of favorable plaque remodeling (e.g., increased smooth 
muscle cell and collagen content and greater vessel stiffness) were 
also evident (148). Administering HSP27 to atheroprone mice 
via bone marrow transplant from HSP27o/e mice or recombi-
nant HSP27 injections also reduced atherosclerotic lesions and 
increased plaque stability (63). These in  vivo findings yielded 
several mechanistic possibilities underlying HSP27-mediated 
atheroprotection. First, the presence of estrogen appears to be 
important for HSP27’s extracellular release. Second, HSP27 could 
modify various processes involved in atherosclerosis, including 
cholesterol homeostasis/trafficking, inflammation, immune 
cell infiltration into and migration out of plaques, activation of 
macrophages to foam cells, and plaque remodeling (Figure 4).
Regulation of Cholesterol in Macrophages by HSP27
An interesting finding from the HSP27 overexpressing athero-
genic mouse model is the reduction in cholesterol, in both plaque 
and serum (148), suggesting that HSP27 is involved in lipid 
homeostasis. One class of receptors known to bind to modified 
lipoproteins and facilitate their internalization in macrophages is 
SR-A (149, 150). It has been suggested that unregulated uptake 
of modified LDL in macrophages promotes the differentiation 
of monocyte-derived macrophages into pro-inflammatory foam 
cells, resulting in their accumulation in the lumen and, con-
sequently, the narrowing and hardening of blood vessels (151, 
152). In vitro experiments from our laboratory have shown that 
extracellular HSP27 affects SR-A activity via protein interactions 
on the surface of macrophages (65). This interaction reduces 
the binding of LDL to SR-A, and consequently, the formation 
of cholesterol-laden macrophages (65, 135). However, recent 
experimental data also support the role of HSP27 as a downregu-
lator of SR-A protein expression (135). It has been shown that 
treatment of macrophages with extracellular recombinant HSP27 
(rHSP27) is associated with reductions in both SR-A mRNA 
levels (−39%) and cell surface expression (−58%) as well as less 
foam cell formation  –  effects that occur via NF-κB signaling 
(135). Knockout of SR-A in ApoE−/− atheroprone mice abrogated 
the protective effects (reductions in atherosclerotic lesions) of 
HSP27, indicating HSP27 atheroprotection appears to depend, 
in part, on the presence of SR-A (135). Recent experiments in 
our laboratory indicate that HSP27 modulates cholesterol efflux 
in macrophages via ABCA1 and ABCG1 transporters (153). 
Thus, HSP27 has numerous, pleiotropic effects on cholesterol 
trafficking, modulating both import and export of cholesterol in 
macrophages (Figure 4).
Modulation of the Inflammatory Response
Less atherosclerotic lesions in HSP27o/e ApoE−/− suggested that 
HSP27 can modulate the immune processes involved in athero-
sclerosis. One possibility lies in HSP27-mediated regulation of 
NF-κB activity in macrophages. NF-κB transcription factors reg-
ulate a vast number and diversity of gene targets, including those 
involved in cell proliferation, apoptosis, the cell stress response, 
inflammation, and both innate and adaptive immune responses 
(154, 155). Normally found in the cytoplasm as inactive dimers 
associated with IκB, NF-κB translocates to the nucleus once IκB is 
phosphorylated by the upstream IκB kinase complex (IKK), lead-
ing to the transactivation of numerous gene targets (154, 156). 
FigURe 4 | extracellular HSP27, whose release is stimulated by estrogen, affects macrophages by (i) reducing ox-LDL uptake and (ii) activating 
NF-κB, which results in increased secretion of iL-10 and gM-CSF (65, 103, 135).
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NF-κB-dependent pathways may influence the inflammatory 
process in atherosclerosis. Various experimental models indicate 
that intracellular HSP27 attenuates NF-κB activation and signal-
ing. In skeletal muscle disuse-mediated atrophy, the activation of 
NF-κB is reversed by HSP27 (157). Cardiac-specific overexpres-
sion of HSP27 was found to be protective against LPS-induced 
cardiac dysfunction in mice via inhibition of the NF-κB pathway 
(158). Also, heat shock treatment, which upregulated HSP27, 
was thought to protect against angiotensin II-induced inflamma-
tion via an inhibitory effect of HSP27 on the NF-κB pathway by 
reducing both phosphorylated and non-phosphorylated IKK-α 
(159, 160). However, several studies show the opposite effect of 
HSP27 on NF-κB. HSP27 overexpression enhances the 26S pro-
teasome and augments the degradation of phosphorylated IκBα. 
As described previously, this leads to the activation and nuclear 
translocation of NF-κB, which the authors suggest is responsible 
for HSP27’s downstream anti-apoptotic properties (161). More 
recently, Park and colleagues found that some pro-inflammatory 
cytokines, such as TNF-α, can enhance the binding of HSP27 to 
other NF-κB protein partners, such as IκB kinases (IKKs), and 
this interaction is promoted by the phosphorylation of HSP27 
(162). While these studies all focused on intracellular actions of 
HSP27, whether extracellular HSP27 has an effect on the NF-κB 
pathway is starting to be explored.
Within atherosclerotic plaque, NF-κB is activated mainly in 
endothelial cells, smooth muscle cells, and macrophages. Based 
on the evidence supporting the role of HSP27 in the activation 
of NF-κB, and also the release of HSP27 from macrophages 
by estrogen (66, 135), it is apparent that extracellular HSP27 
may also contribute to NF-κB signaling during atherosclerosis 
(Figure  4). Indeed, macrophages exposed to an extracellular 
recombinant HSP27 (rHSP27) consistently activated NF-κB 
through the degradation of IκBα. This effect was followed by a 
change in the transcriptional profile of some target genes coding 
for pro- and anti-inflammatory cytokines, such as IL-6, GM-CSF, 
TNF, or IL-10 (103), confirming the evidence that cytokines are 
implicated at various stages of atherosclerosis. Moreover, it was 
also shown that HSP27 attenuated ac-LDL-induced release of the 
pro-inflammatory cytokine, IL-1β, while increasing secretion 
of the anti-inflammatory cytokine, IL-10, in macrophages (65). 
Previous findings in primary human monocytes support this anti-
inflammatory role, as extracellular rHSP27 significantly induced 
IL-10 production and only minimally upregulated TNF-α (107).
Protection of the Endothelial Vasculature from 
Oxidative Stress and Apoptosis
Extracellular HSP27 may also protect the endothelium from 
various stress factors inherent in the vasculature. The vessel wall 
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and subendothelial space are continually exposed to stress from 
hemodynamic strain, as well as damaging factors within the blood 
itself (i.e., pro-inflammatory molecules, pathogens, carcinogens, 
and products of oxidative stress). Reactive oxygen species (ROS) 
can modify LDLs in the blood, turning it into ox-LDL, which has 
been shown to activate NADPH oxidase and xanthine oxidase, 
thereby inducing oxidative stress (163). Additionally, exposure 
of endothelial cells to LDL and ox-LDL increases the levels of the 
ROS species, O2−, and NO (164, 165). During oxidative stress, 
HSP27 functions as an antioxidant in cells, lowering the levels 
of ROS by reducing the levels of intracellular iron and raising 
intracellular levels of glutathione (166). HSP27’s presence in 
the circulation may therefore affect ox-LDL’s contribution 
to atherogenesis on two levels  –  by competing with its uptake 
into macrophages (Figure 4) (65) and by lowering intracellular 
ROS production in endothelial cells, which would then curb 
the subsequent oxidative modification of LDL in the blood. An 
additional cardioprotective effect stems from the ability of HSP27 
to protect the endothelium from ischemic insult by maintaining 
the integrity of cytoskeletal proteins (167–171). HSP27 can also 
preserve the endothelial barrier by functioning as a general 
anti-apoptotic protein, since downregulation of HSP27 in retinal 
capillary endothelial cells by both cytokines and siRNA increased 
apoptosis (172). Thus, HSP27-based treatment strategies – which 
could potentially prevent LDL oxidative modification as well as 
protect the endothelium/accelerate its repair – may be effective 
in reducing lesion formation. Although the majority of the above 
findings related to endothelium protection involve intracellular 
HSP27, recent results from our laboratory implicate extracellular 
HSP27 in the regeneration of the endothelial barrier (105). Using 
primary human EPCs treated with rHSP27 and mice overex-
pressing HSP27 (HSP27o/e mice), it was found that after vascular 
injury, re-endothelialization improved in both the experimental 
models, and neointima formation was decreased in HSP27o/e 
mice compared to wild type  –  effects partly mediated through 
the secretion of VEGF and its paracrine effect on EPCs (105).
FUTURe DiReCTiONS
By mediating the immunological process of atherosclerosis 
(Figures  3 and 4) and attenuating disease symptoms and pro-
gression, HSP27 has considerable therapeutic potential in the 
treatment of cardiovascular diseases. Currently, our laboratory is 
considering several strategies to capitalize on the atheroprotective 
effect of HSP27 via its emerging role as an immune modulator.
The first and simplest approach is to administer HSP27 to 
patients. Indeed, as described above, in mice prone to develop-
ing atherosclerosis, subcutaneous injections of rHSP27 reduced 
lesion formation and total cholesterol levels (63). Although these 
preclinical findings in animal models are encouraging, several 
questions remain in the context of its application in the clinical 
setting  –  for example, what is the best route of administration 
(subcutaneous vs. intravenous injection vs. oral intake)? Also, 
what is the most effective formulation (the complete HSP27 
protein vs. an HSP27 protein fragment)? An important caveat to 
keep in mind as well is that the administration of HSP27 may 
pose risks in the case of cancer, since extracellular HSP27 has been 
shown to promote (i) the transendothelial migration of primary 
tumor cells (49) and (ii) the differentiation of macrophages to 
phenotypes that tolerate human breast cancer cell progression 
(48). One must therefore carefully weigh the advantages and 
disadvantages concerning exogenous administration of HSP27 
as a therapeutic strategy in atherosclerosis.
Another approach to consider is to harness the organism’s 
inherent immunity when exposed to rHSP27. The discovery in 
our laboratory of HSP27 being complexed with AAB in the blood 
(thus confounding its detection through conventional ELISA kits) 
led to the development of a more sensitive, mass spectrometric-
based detection assay, as well as mechanistic insight into how 
HSP27 exists/functions outside the cell. Our preliminary studies 
suggest that HSP27 AAB may, in fact, have salutary effects on 
HSP27 signaling and atheroprotection (67). The existence of AAB 
against HSPs in the context of atherosclerosis is not new –  for 
example, antibodies generated against microbial HSP60 may 
cross-react with endogenous HSP60 expressed in the vessel 
lumen (molecular mimicry), enhancing inflammation and pro-
moting atherosclerosis (173). HSP27 AAB are present in other 
disease states like cancer (174) and acute heart disease (175–177), 
although it is difficult to gage how levels correlate with disease. 
Higher antibody titers are associated with improved survival of 
breast cancer patients, but elevations also correlate with adverse 
conditions, such as metabolic syndrome (177) and the early 
phase of acute coronary syndromes (e.g., myocardial infarction 
and unstable angina) – although in acute coronary syndromes, 
HSP27 antibody levels rapidly fall after a brief spike (175). It is 
still unclear how HSP27 AAB are linked to CVD – one study cor-
related elevations with CVD (176), while other findings indicate 
the opposite, that HSP27 autoantibody titers (67, 178) are higher 
in healthy control subjects compared to CVD patients. Indeed, if 
the presence of HSP27 antibodies complexed to HSP27 promotes 
atheroprotection, immunization strategies, either active (vis-à-
vis injection with an HSP27-derived antigenic peptide with or 
without adjuvant) or passive (administration of the antigenic 
peptide combined with already generated AAB), could provide 
exciting, new therapeutic possibilities.
Finally, there are alternative methods for boosting HSP27 func-
tion. For example, some microRNAs (“miRs,” which are 20–22 nt-
long non-coding RNA molecules that regulate gene expression by 
binding to nascent mRNA transcripts, targeting them for degra-
dation), which downregulate HSP27 mRNA transcripts, can be 
targeted for degradation by its complimentary sequence, known 
as “miR inhibitor” or “anti-miR” (179, 180). Proof of this principle 
has been demonstrated in an insulin-resistance rat model, where 
decreased expression of miR-1 and miR-133 increased the level 
of HSP27, contributing to the loss of muscle adaptability (181). 
Our laboratory is currently investigating which miR species are 
specifically upregulated in atherosclerosis and whether these 
alter HSP27 levels; if so, there is a potential to target such miRs 
with anti-miR therapy in atherosclerosis patients. There are also 
endogenous methods of increasing levels of circulating HSPs – for 
example, a huge literature already exists correlating exercise with 
increased serum HSP levels (182). In light of a recent Finnish 
study linking frequency of sauna use with reduced risk of CVD 
(183), it appears that subjecting the body to periods of mild to 
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moderate heat stress may be very beneficial for the health. These 
sentiments – extolling the virtues of heat – are best expressed by 
a quote attributed to the ancient sage and physician Hippocrates: 
“That which drugs fail to cure, the scalpel can cure. That which 
the scalpel fails to cure, heat can cure. If the heat cannot cure, it 
must be determined to be incurable” (184, 185). By modulating 
atheroprogression through cross talk with the immune system, 
strategies that increase HSP27 levels are promising therapeutic 
approaches to consider.
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